OPINION

TOP STORIES

MEDICAL DEVICES

KEY THEMES

ARCHIVE & SEARCH

SIGN UP

LOG IN

COUNTRIES COVERED THIS MONTH

105 NEW stories in THIS MONTH
7.972 stories IN THE SITE since 2015

Forecasting & Launch Pricing Tool  

LIGHT - CONTENT AVAILABLE WITHOUT SUBSCRIPTION

 

KEY THEMES

 

About Akceso

Akceso Advisors A.G. offers professional support in the field of market patient access and pricing to the pharmaceutical industry. In the past decade, we had numerous success stories, delivering valuable market input for both leading pharmaceutical companies and SMEs worldwide. Our international team supports every client carrying out major-impact payer and pricing strategy projects, with the help of our state-of-the-art Verity Prices database and our cutting-edge international reference pricing tools.

CONTACT US:
Phone: +41 61 225 4393
Fax: +41 61 225 4391
Email: [email protected]
Website: https://akceso.ch/
Address: Akceso Advisors AG Aeschengraben 29. CH-4051 Basel Switzerland
Visit Our Website  

ABOUT THIS SITE

In our newsletter we provide a monthly view of developments in pricing, reimbursement, and market access across the globe. Since its launch in June 2015, we have covered more than 7,000 stories from over 100 countries. On this site, you can find all of the stories from the beginning and we update it monthly.

This is the Home page, here you can find the headlines of the recent news.

Already have an account?  Click on LOG IN button at the top of the page and enjoy the full functionality of the site! Read the full Opinion, the news extracts or use ARCHIVE & SEARCH page for all news in the past. 

Don't have an account yet?  Go to the "Light - Content available without subscription" section, you can read some selected news here. Use SIGN UP button at the top of the page to request access and use all features including opinion, archive and search.

Having any question, please contact us at [email protected]

Visit our website and read more about the features of our service!

READ MORE

OPINION

UK’S VPAS – WHAT HAPPENS WHEN VOLUNTEERS STOP VOLUNTEERING?

The UK is one of the few countries that does not have an official reference pricing system, with companies in theory free to set prices at whatever level they feel is appropriate. However, pricing is in practice a highly sensitive issue, controlled via a combination of the long-established HTA body NICE and two pricing schemes: the Statutory Scheme that currently imposes a set rebate of 27.5% on sales of pharmaceuticals to the National Health Service above a set 1.1% growth rate, and the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS). These are the latest versions of pricing agreements between the National Health Service and Pharmaceutical Industry that stretch back to the 1950s. Around 90% of manufacturers have chosen to be part of the VPAS, which has made recent major rebate increases highly controversial.

Is the UK pharmaceutical market financially viable?

The current VPAS agreement started in 2019 and expires at the end of 2023. The issue for Pharma companies is that the capped payback, set (in 2019) at 6.88% when sales exceed more than 2% annual growth, increased in 2022 to...

READ THE FULL ARTICLE

 

TOP STORIES

Forecasting & Launch Pricing Tool  

ASIA PACIFIC

 

EUROPE

 

LATIN AMERICA

 

MIDDLE EAST & AFRICA

 

NORTH AMERICA

 

MEDICAL DEVICES